Italia markets closed
FTSE MIB
33.812,44 +41,37 (+0,12%) Dow Jones
40.589,34 +654,27 (+1,64%) Nasdaq
17.357,88 +176,16 (+1,03%) Nikkei 225
37.667,41 -202,10 (-0,53%) Petrolio
76,44 -1,84 (-2,35%) Bitcoin EUR
62.378,99 +701,64 (+1,14%)
AbbVie Inc. (0QCV.L)
LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 07:14PM BST
| Chiusura precedente | 146,95 |
| Aperto | 147,24 |
| Denaro | 0,00 x N/D |
| Domanda | 0,00 x N/D |
| Min-Max giorno | 150,54 - 154,06 |
| Intervallo di 52 settimane | 131,22 - 167,80 |
| Volume | |
| Media Volume | 108.198 |
| Capitalizzazione | 219,147B |
| Beta (mensile su 5 anni) | 0,62 |
| Rapporto PE (ttm) | 0,21 |
| EPS (ttm) | 6,97 |
| Prossima data utili | 25 ott 2024 - 29 ott 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAlector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Data readout expected in Q4 2024SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Data from the trial are expected in the fourth quarter of 2024. AL00
© 2024 Yahoo. Tutti i diritti riservati.